HRP20171693T1 - Farmaceutski pripravak koji sadrži (1r, 4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i ibuprofen - Google Patents
Farmaceutski pripravak koji sadrži (1r, 4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i ibuprofen Download PDFInfo
- Publication number
- HRP20171693T1 HRP20171693T1 HRP20171693TT HRP20171693T HRP20171693T1 HR P20171693 T1 HRP20171693 T1 HR P20171693T1 HR P20171693T T HRP20171693T T HR P20171693TT HR P20171693 T HRP20171693 T HR P20171693T HR P20171693 T1 HRP20171693 T1 HR P20171693T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmacologically active
- active ingredient
- pain
- dosage form
- pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 title claims 2
- 229960001680 ibuprofen Drugs 0.000 title claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 239000002831 pharmacologic agent Substances 0.000 claims 12
- 239000002552 dosage form Substances 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 230000003040 nociceptive effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001107 psychogenic effect Effects 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical class O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (13)
1. Farmaceutski pripravak koji sadrži:
a) prvi farmakološki aktivni sastojak koji je izabran od spoja prema formuli (I)
[image]
i njihove fiziološki prihvatljive soli, i
b) drugi farmakološki aktivni sastojak, koji je derivat propionske kiseline odabran iz skupine koja sadrži ibuprofen i njihove fiziološki prihvatljive soli.
2. Farmaceutski pripravak prema zahtjevu 1, naznačen time da je prvi farmakološki aktivni sastojak spoj prema formuli (I)
[image]
3. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da sadrži prvi i drugi farmakološki aktivni sastojak u takvom masenom omjeru da će nakon davanja pacijentu imati sinergističko terapeutsko djelovanje.
4. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da je relativni omjer mase prvog farmakološki aktivnog sastojka prema drugom farmakološki aktivnom sastojku unutar raspona od 1 : 30 do 1 : 1,000,000.
5. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva naznačen time da je za uporabu za sprječavanje ili liječenje boli.
6. Farmaceutski pripravak prema zahtjevu 5, naznačen time da bol je:
- periferna, središnja ili mišićna skeletna bol; i/ili
- akutna, subakutna ili kronična bol; i/ili
- umjerena do jaka bol; i/ili
- neuropatska ili psihogena ili nociceptivna ili miješana bol; i/ili
- bol u donjem dijelu leđa, visceralna bol ili glavobolja; i/ili
- postoperativna (post-kirurška) bol, rak ili upalna bol.
7. Farmaceutski oblik doziranja naznačen time da sadrži farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva.
8. Farmaceutski oblik doziranja prema zahtjevu 7, naznačen time da sadrži prvi farmakološki aktivni sastojak u dozi od 10 do 1,200 µg.
9. Farmaceutski oblik doziranja prema zahtjevu 7 ili 8, naznačen time da sadrži drugi farmakološki aktivni sastojak u dozi od 0.05 do 5 g.
10. Farmaceutski oblik doziranja prema bilo kojem od zahtjeva 7 do 9, naznačen time da je doziranje prvog farmakološki aktivnog sastojka u rasponu od 1:20 do 20:1 količine koja je ekvivalentno djelotvorna doziranju drugog farmakološki aktivnog sastojka.
11. Farmaceutski oblik doziranja prema bilo kojem od zahtjeva 7 do 10, naznačen time da je za oralnu, intravensku, intraperitonealnu, transdermalnu, intratekalnu, intramuskularnu, intranazalnu, transmukoznu, potkožnu ili rektalnu primjenu.
12. Komplet koji sadrži prvi farmaceutski oblik doziranja koji sadrži prvi farmakološki aktivni sastojak kako je definiran u zahtjevu 1 ili 2, i drugi farmaceutski oblik doziranja koji sadrži drugi farmakološki aktivni sastojak kako je definiran u patentnom zahtjevu 1.
13. Komplet prema zahtjevu 12, naznačen time da su prvi i drugi farmaceutski oblik doziranja prilagođeni za istovremenu ili uzastopnu primjenu, bilo istim ili različitim putem primjene.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12003935 | 2012-05-18 | ||
| PCT/EP2013/001466 WO2013170967A1 (en) | 2012-05-18 | 2013-05-16 | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
| EP13723672.5A EP2849745B1 (en) | 2012-05-18 | 2013-05-16 | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and ibuprofen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171693T1 true HRP20171693T1 (hr) | 2017-12-15 |
Family
ID=48468206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171693TT HRP20171693T1 (hr) | 2012-05-18 | 2017-11-06 | Farmaceutski pripravak koji sadrži (1r, 4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i ibuprofen |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9320729B2 (hr) |
| EP (1) | EP2849745B1 (hr) |
| JP (1) | JP6116674B2 (hr) |
| CN (1) | CN104284659A (hr) |
| AU (1) | AU2013262073B2 (hr) |
| BR (1) | BR112014028571A2 (hr) |
| CA (1) | CA2873656A1 (hr) |
| CY (1) | CY1119786T1 (hr) |
| DK (1) | DK2849745T3 (hr) |
| EA (1) | EA028200B1 (hr) |
| ES (1) | ES2658216T3 (hr) |
| HK (1) | HK1204942A1 (hr) |
| HR (1) | HRP20171693T1 (hr) |
| HU (1) | HUE035112T2 (hr) |
| IL (1) | IL235655B (hr) |
| LT (1) | LT2849745T (hr) |
| MX (1) | MX354687B (hr) |
| NO (1) | NO2849745T3 (hr) |
| PL (1) | PL2849745T3 (hr) |
| PT (1) | PT2849745T (hr) |
| RS (1) | RS56771B1 (hr) |
| SI (1) | SI2849745T1 (hr) |
| WO (1) | WO2013170967A1 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130310435A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
| US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
| US9855286B2 (en) | 2012-05-18 | 2018-01-02 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component |
| US20130310385A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants |
| JP6673924B2 (ja) | 2015-01-23 | 2020-03-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB971700A (en) | 1961-02-02 | 1964-09-30 | Boots Pure Drug Co Ltd | Anti-Inflammatory Agents |
| JPS584720A (ja) | 1981-06-26 | 1983-01-11 | ザ・アツプジヨン・カンパニ− | 鎮痛用医薬組成物 |
| US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4404208A (en) | 1982-06-30 | 1983-09-13 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and tiflamizole |
| IE55189B1 (en) * | 1982-07-08 | 1990-06-20 | Wyeth John & Brother Ltd | Pharmaceutical compositions |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| EP0189788B1 (de) | 1985-01-23 | 1989-09-13 | ASTA Pharma Aktiengesellschaft | Synergistische Kombination von Flupirtin und nicht-steroidalen Antiphlogistika |
| EP0473655B1 (en) | 1989-05-22 | 1997-01-15 | Biochemical Veterinary Research Pty. Ltd. | Divalent metal salts of indomethacin |
| CA2112378A1 (en) | 1991-07-04 | 1993-01-21 | Masakazu Kanazawa | Analgesic preparation |
| JPH05221857A (ja) | 1992-02-14 | 1993-08-31 | Arakusu:Kk | 配合解熱鎮痛剤 |
| US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| US5330761A (en) | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
| CA2163995A1 (en) | 1993-06-07 | 1994-12-22 | Malcolm Maccoss | Spiro-substituted azacycles as neurokinin antagonists |
| US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5399362A (en) | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
| US5914129A (en) | 1996-07-23 | 1999-06-22 | Mauskop; Alexander | Analgesic composition for treatment of migraine headaches |
| RS49982B (sr) | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
| US6713089B1 (en) | 1998-09-10 | 2004-03-30 | Nycomed Danmark A/S | Quick release pharmaceutical compositions of drug substances |
| ES2194536T3 (es) | 1998-11-13 | 2003-11-16 | Lilly Co Eli | Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos. |
| ATE279920T1 (de) | 2000-12-28 | 2004-11-15 | Fresenius Kabi Austria Gmbh | Stabile infusionslösung von diclofenac-salzen, deren herstellung und verwendung |
| BR0307268A (pt) | 2002-01-28 | 2004-12-14 | Pfizer | Compostos de espiropiperidina n-substituìda como ligantes para o receptor orl-1 |
| PT1374906E (pt) | 2002-06-17 | 2007-07-24 | Chiesi Farma Spa | Um processo para a preparação de compostos de inclusão de piroxicam: beta-ciclodextrina |
| DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DE10257824B4 (de) | 2002-12-10 | 2004-11-11 | Kochem, Hans-Günter, Dr. | Zusammensetzung zur Schmerzbehandlung, insbesondere zur Behandlung von Gelenkschmerzen |
| US20100297252A1 (en) | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
| US7132452B2 (en) | 2003-03-10 | 2006-11-07 | Fang-Yu Lee | Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection |
| DE10360792A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| EP1893610A2 (en) | 2005-06-17 | 2008-03-05 | Pfizer, Inc. | Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists |
| RU2442576C2 (ru) | 2006-04-28 | 2012-02-20 | Грюненталь Гмбх | Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол |
| DK2012763T3 (da) | 2006-04-28 | 2011-05-02 | Gruenenthal Gmbh | Farmaceutisk kombination omfattende 3-(3-dimethylamono-1-ethyl-2-methyl-propyl) phenol og et NSAID |
| CN101147735A (zh) | 2006-09-19 | 2008-03-26 | 沈阳华泰药物研究有限公司 | 注射用药物组合物及其药盒 |
| DE102006046745A1 (de) | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
| DE102006056458A1 (de) | 2006-11-28 | 2008-05-29 | Grünenthal GmbH | Arzneimittelzubereitung von Tramadol und Acetaminophen |
| ES2416723T3 (es) | 2007-10-09 | 2013-08-02 | Merck Patent Gmbh | Composiciones farmacéuticas que contienen benfotiamina y gabapentina |
| CN100560061C (zh) | 2008-06-20 | 2009-11-18 | 海南锦瑞制药股份有限公司 | 一种氯诺昔康冻干粉针剂及其制备方法 |
| EP2331087A1 (en) | 2008-09-05 | 2011-06-15 | Grünenthal GmbH | Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3 diol and paracetamol |
| MX2011002339A (es) | 2008-09-05 | 2011-04-04 | Gruenenthal Gmbh | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propi l)-fenol y un antiepileptico. |
| AR073495A1 (es) | 2008-09-05 | 2010-11-10 | Gruenenthal Gmbh | Combinacion farmaceutica que contiene el 6-dimetilaminometil-1- (3-metoxi-fenil)-ciclohexano-1,3-diol y un nsaid |
| PL2600838T3 (pl) * | 2010-08-04 | 2016-02-29 | Gruenenthal Gmbh | Farmaceutyczna postać dawkowania zawierająca 6'-fluoro-(N-metylo- lub N,N-dimetylo)-4-fenylo-4'9'-dihydro-3'H-spiro[cykloheksano-1,1'-pirano[3,4b]indolo]-4-aminę |
| PL2600846T3 (pl) * | 2010-08-04 | 2016-05-31 | Gruenenthal Gmbh | Farmaceutyczna postać dawki zawierająca 6'-fluoro-(n-metylo- albo N,N-dimetylo-)-4-fenylo-4',9'-dihydro-3'H-spiro[cykloheksano-1,1'-pirano[3,4,b]indol]-4-aminę |
| US20120034297A1 (en) * | 2010-08-04 | 2012-02-09 | Gruenenthal Gmbh | Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
| US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
-
2013
- 2013-05-13 US US13/892,786 patent/US9320729B2/en active Active
- 2013-05-16 AU AU2013262073A patent/AU2013262073B2/en not_active Ceased
- 2013-05-16 WO PCT/EP2013/001466 patent/WO2013170967A1/en active Application Filing
- 2013-05-16 PT PT137236725T patent/PT2849745T/pt unknown
- 2013-05-16 ES ES13723672.5T patent/ES2658216T3/es active Active
- 2013-05-16 CN CN201380025641.6A patent/CN104284659A/zh active Pending
- 2013-05-16 MX MX2014013148A patent/MX354687B/es active IP Right Grant
- 2013-05-16 EA EA201401266A patent/EA028200B1/ru not_active IP Right Cessation
- 2013-05-16 RS RS20180056A patent/RS56771B1/sr unknown
- 2013-05-16 DK DK13723672.5T patent/DK2849745T3/en active
- 2013-05-16 SI SI201330918T patent/SI2849745T1/en unknown
- 2013-05-16 BR BR112014028571A patent/BR112014028571A2/pt not_active IP Right Cessation
- 2013-05-16 CA CA2873656A patent/CA2873656A1/en not_active Abandoned
- 2013-05-16 EP EP13723672.5A patent/EP2849745B1/en active Active
- 2013-05-16 NO NO13723672A patent/NO2849745T3/no unknown
- 2013-05-16 HU HUE13723672A patent/HUE035112T2/en unknown
- 2013-05-16 JP JP2015511953A patent/JP6116674B2/ja active Active
- 2013-05-16 LT LTEP13723672.5T patent/LT2849745T/lt unknown
- 2013-05-16 PL PL13723672T patent/PL2849745T3/pl unknown
-
2014
- 2014-11-12 IL IL235655A patent/IL235655B/en active IP Right Grant
-
2015
- 2015-06-11 HK HK15105573.7A patent/HK1204942A1/xx not_active IP Right Cessation
-
2016
- 2016-03-21 US US15/075,606 patent/US10076510B2/en active Active
-
2017
- 2017-11-06 HR HRP20171693TT patent/HRP20171693T1/hr unknown
-
2018
- 2018-01-16 CY CY20181100052T patent/CY1119786T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2849745T3 (pl) | 2018-04-30 |
| US20130324581A1 (en) | 2013-12-05 |
| CY1119786T1 (el) | 2018-06-27 |
| US20160199349A1 (en) | 2016-07-14 |
| US10076510B2 (en) | 2018-09-18 |
| EP2849745B1 (en) | 2017-11-01 |
| MX354687B (es) | 2018-03-15 |
| RS56771B1 (sr) | 2018-04-30 |
| HUE035112T2 (en) | 2018-05-02 |
| AU2013262073B2 (en) | 2018-01-18 |
| US9320729B2 (en) | 2016-04-26 |
| MX2014013148A (es) | 2015-01-19 |
| IL235655B (en) | 2018-08-30 |
| JP2015516447A (ja) | 2015-06-11 |
| AU2013262073A1 (en) | 2015-01-22 |
| EP2849745A1 (en) | 2015-03-25 |
| CN104284659A (zh) | 2015-01-14 |
| EA028200B1 (ru) | 2017-10-31 |
| WO2013170967A1 (en) | 2013-11-21 |
| EA201401266A1 (ru) | 2016-05-31 |
| BR112014028571A2 (pt) | 2017-06-27 |
| CA2873656A1 (en) | 2013-11-21 |
| IL235655A0 (en) | 2015-01-29 |
| DK2849745T3 (en) | 2017-12-04 |
| LT2849745T (lt) | 2018-01-25 |
| PT2849745T (pt) | 2018-02-07 |
| SI2849745T1 (en) | 2018-03-30 |
| NO2849745T3 (hr) | 2018-03-31 |
| JP6116674B2 (ja) | 2017-04-19 |
| ES2658216T3 (es) | 2018-03-08 |
| HK1204942A1 (en) | 2015-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171693T1 (hr) | Farmaceutski pripravak koji sadrži (1r, 4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i ibuprofen | |
| HRP20200665T1 (hr) | Bifenilsulfonamidni antagonist receptora za endotelin i angiotenzin ii za liječenje glomeruloskleroze i iga-inducirane nefropatije | |
| HRP20190500T1 (hr) | Farmaceutska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola i pregabalina ili gabapentina | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| HK1182619A1 (zh) | 用於局部給藥的螺-羥吲哚化合物的藥物組合物及其作為治療劑的用途 | |
| JP2015504871A5 (hr) | ||
| WO2013090278A3 (en) | Intranasal dexmedetomidine compositions and methods of use thereof | |
| JP2018505169A5 (hr) | ||
| CO6630134A2 (es) | Formulación orales y sales lipofílicas de metilnaltrexona | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| JP2012180381A5 (hr) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| SG10201804024VA (en) | Formulations of azaindole compounds | |
| TN2013000293A1 (en) | Derivatives of azaindazole or diazaindazole type as medicament | |
| WO2013158680A3 (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| WO2012079092A3 (en) | Testosterone undecanoate compositions | |
| HRP20230272T1 (hr) | Postupci za liječenje cistične fibroze | |
| HRP20150375T1 (hr) | Derivati piridazinona | |
| WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| JP2012236834A5 (hr) | ||
| TN2012000493A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations | |
| HRP20150648T1 (hr) | Sastavi za lijeäśenje raka | |
| HRP20171708T1 (hr) | FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I GABAPENTINOID | |
| RU2018135967A (ru) | Интраназальные фармацевтические композиции на основе бензодиазепина | |
| HRP20191322T1 (hr) | Antitumorska kombinacija koja sadži kabazitaksel i cisplatin |